VEGF is a well-established key-factor inducing angiogenesis leading to tumour growth and metastasis.1,2 There exists a significant correlation between tumour microvessel density in breast cancer, the presence of axillary lymph node and distant metastases, respectively.3 VEGF over-expression is frequently observed in Her2/neu positive patients with breast cancer.4,5 Via multiple intracellular pathways VEGF and Her2/neu act at various stages of breast cancer development.6 Over-expression of the proto-oncogene Her2/neu is associated with an up-regulation of VEGF in vitro and in vivo. This evidence concerns the gene ERBB2 and breast carcinoma.